Back to Search
Start Over
Comparative Contralateral Randomized Clinical Trial of Standard (3 mW/cm 2 ) Versus Accelerated (9 mW/cm 2 ) CXL in Patients With Down Syndrome: 3-Year Results.
- Source :
-
Journal of refractive surgery (Thorofare, N.J. : 1995) [J Refract Surg] 2022 Jun; Vol. 38 (6), pp. 381-388. Date of Electronic Publication: 2022 Jun 01. - Publication Year :
- 2022
-
Abstract
- Purpose: To compare the long-term results of accelerated corneal cross-linking (CXL) (9 mW/cm <superscript>2</superscript> , 10 min) with standard CXL (3 mW/cm <superscript>2</superscript> , 30 min) in patients with Down syndrome who had keratoconus.<br />Methods: In this contralateral randomized clinical trial, 27 patients with Down syndrome aged 15.78 ± 2.46 years (range: 10 to 19 years) were enrolled. CXL was performed using the KXL System (Avedro, Inc) under general anesthesia, and patients were followed up for 3 years. The main outcome measure was a change in average keratometry in the 3-mm zone around the steepest point (zonal Kmax-3mm). Secondary outcomes were changes in Corvis ST (Oculus Optikgeräte GmbH) biomechanical parameters and vision, refraction, and corneal tomography measurements.<br />Results: Mean 3-year changes in zonal Kmax-3mm were not significantly different between the accelerated and standard groups (-0.06 ± 0.75 and -0.35 ± 0.94 diopters [D], respectively, P = .727). Despite the contralateral design of the study, based on most baseline biomechanical indices, corneas in the standard group were weaker before treatment. The standard group also showed significantly fewer 3-year changes in the stress-strain index (-0.11 ± 0.21 vs -0.30 ± 0.32), integrated radius (+0.99 ± 3.48 vs +3.14 ± 2.84), and deformation amplitude ratio-2mm (-1.38 ± 1.33 vs +0.30 ± 1.75) (all P < .0167). Corneal stiffness in the accelerated group was stable for 2 years, and the decline mainly occurred during the third year.<br />Conclusions: In young patients with Down syndrome who had keratoconus, accelerated and standard CXL showed a similar flattening effect. Standard CXL is better able to maintain corneal stiffness in weaker corneas. With accelerated CXL, despite stable results for 2 years, there was decreased corneal stiffness in the third year. Longer follow-up periods are warranted to study the decreased efficacy on keratoconus progression. [ J Refract Surg . 2022;38(6):381-388.] .
- Subjects :
- Collagen therapeutic use
Corneal Topography
Cross-Linking Reagents therapeutic use
Follow-Up Studies
Humans
Photosensitizing Agents therapeutic use
Riboflavin therapeutic use
Ultraviolet Rays
Down Syndrome complications
Down Syndrome drug therapy
Keratoconus drug therapy
Photochemotherapy methods
Subjects
Details
- Language :
- English
- ISSN :
- 1081-597X
- Volume :
- 38
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of refractive surgery (Thorofare, N.J. : 1995)
- Publication Type :
- Academic Journal
- Accession number :
- 35686709
- Full Text :
- https://doi.org/10.3928/1081597X-20220329-01